摘要
近年来失眠的药物治疗已成为全球研究人员面临的挑战。用于治疗失眠症的常规治疗药物是苯二氮类(BZD)(和非BZD(也称为z-药物)、三环抗抑郁药(TCA)多塞平以及褪黑素激动剂,但由于这些药物的重大副作用(如:宿醉反应、依赖性、耐受性、反弹失眠、肌肉酸痛、呼吸系统抑制、认知功能障碍和焦虑增加等),使得他们解决睡眠问题的潜力受到限制。最近研究发现,食欲素神经肽是调节觉醒与睡眠之间的转变的一种因子,可帮助从过渡状态转为觉醒状态,作为治疗睡眠障碍的可能治疗靶标,与常规治疗相比具有较小副作用的优点。笔者对食欲素受体拮抗剂用于失眠症治疗的研究进展进行综述。
In recent years,drug therapy for insomnia has become a challenge for researchers around the world.The conventional therapeutic agents for the treatment of insomnia are benzodiazepine(BZD)and non-BZD(also known as z-drug),tricyclic antidepressants(TCA)doxepin and melatonin agonists.But because of the significant side effects of these drugs(eg.hangover,dependency,tolerance,rebound,insomnia,respiratory depression,respiratory dysfunction,cognitive dysfunction and increased anxiety),their potential to solve sleep problems is limited.Recent studies have shown that orexin-like neuropeptides are a factor in regulating the transition between awakening and sleep,helping to switch from a transitional state to a conscious state as a possible therapeutic target for the treatment of sleep disorders,with less side effects than conventional therapy.This review focuses on the progress of orexin receptor antagonists as a sleep drug.
作者
潘英
倪海华
Pan Ying;Ni Haihua(Department of Pharmacy,Cancer Hospital of Jiangsu Province,Nanjing,Jiangsu 210009,China;Department of Haining Phavmaceutical,Yangtze River Pharmaceutical Group,Taizhou,Jiangsu 225321,China)
出处
《中国基层医药》
CAS
2020年第9期1149-1152,共4页
Chinese Journal of Primary Medicine and Pharmacy
